Biomed Grants Race Post-Shutdown: NIH's Urgent Hideaway
Published Date: 11/28/2025
Notice
Summary
The NIH’s Center for Scientific Review is holding a closed virtual meeting on December 17, 2025, to review important biomedical research grant applications. This meeting was delayed due to a government shutdown but is now urgent to keep funding on track for key health projects. Scientists and researchers waiting on NIH grants are the ones affected, with no direct cost changes but a tight timeline to keep research moving.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Urgent rescheduled NIH grant review
The NIH is holding a virtual grant review meeting on December 17, 2025 (9:00 a.m. to 6:00 p.m.) that was delayed by a 43-day government shutdown. Scientists and researchers waiting on NIH grant evaluations are affected because the meeting is urgent to allow timely funding recommendations, and the notice was published less than 15 days before the meeting. There are no direct cost changes stated, but the timeline to keep research funding on track is tight.
Meeting closed to public for privacy
The meeting on December 17, 2025 will be closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) because discussions could disclose confidential trade secrets, commercial property, patentable material, or personal information. That means the public cannot attend or observe the grant application reviews that day.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-21350, Certain Liquid Crystal Display Devices, Components Thereof, and Products Containing the Same; Notice of Institution of Investigation
The U.S. International Trade Commission is launching an investigation into certain liquid crystal display (LCD) devices and their parts because some companies say these products break their patents. This affects businesses importing or selling these LCD products in the U.S., and could lead to import bans or sales stops soon. Keep an eye out—this could shake up the LCD market and impact money flow starting late 2025 or early 2026.
Next: 2025-21352, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on January 20, 2026, to review grant applications focused on improving vaccine effectiveness. These meetings are private to protect sensitive information like trade secrets and personal details. Scientists and researchers applying for grants should note this important review date, but no new costs or changes to funding are announced.